Addressing Methodological Challenges with Clinical Trials of Psychotomimetic Agents
This upcoming NIMH grant will fund research to improve clinical trial methods for studying psychedelics like psilocybin, ketamine, and MDMA in treating mental health disorders.
Funder: National Institutes of Health
Due Dates: October 11, 2026
Funding Amounts: Estimated total program funding: $5,500,000; ~5 awards expected; typical R01 duration up to 5 years.
Summary: Supports research to address methodological challenges in clinical trials of rapid-acting psychotropic interventional drugs (RAPIDs) and optimize their delivery and effectiveness.
Description
This funding opportunity seeks to improve the rigor and generalizability of clinical trials for rapid-acting psychotropic interventional drugs (RAPIDs). The goal is to elucidate the therapeutic effects of RAPIDs by addressing methodological challenges in trial design, implementation, and analysis. The initiative also aims to advance understanding of how RAPIDs and adjunctive psychosocial interventions can be optimally delivered, monitored, and sustained to enhance their effectiveness and applicability in diverse clinical settings. Supported studies should focus on methodological innovations that increase the interpretability of clinical trial data and the generalizability of results.
